Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
450 participants
OBSERVATIONAL
2021-07-15
2026-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
A number of patients will be enrolled in a sub-study investigating the neuronal-enteroendocrine-hypothalamic axis.
Gut hormone study. Our hypothesis is that proinflammatory cytokines produced by the tumour can not only affect appetite directly through the vagal and the central melanocortin system but also indirectly though the enhanced EEC activity; either through increased number or increased function.
In this study, the investigators will explore and compare the pattern and levels (pre-prandial and post prandial) of the pro-inflammatory cytokines and gut hormones between stage-standardised anorexic and non-anorexic cancer patients and age-matched healthy controls.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Muscle Dysfunction in Gastrointestinal or Hepatobiliary Cancer
NCT03347162
Micrometastasis in Gastrointestinal Cancer
NCT01919151
TDM for Optimized Outcome in Patients With mRCC.
NCT04659343
Evaluation of Preoperative Investigations in Patients With Liver Cancer
NCT00408122
A Longitudinal Study of Colorectal Cancer Patients With Metastatic Disease in Middle-Norway
NCT02395224
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
However the relationship between different markers of nutritional status and body composition with fitness is not fully understood. It is also not known what impact dietetic interventions have on the reduced survival seen in patients with weight loss at baseline.
Finally, the underlying interaction between the neuronal-enteroendocrine-hypothalamic axis that regulates appetite is poorly understood but believed to be impaired in patients with upper GI cancers because of a number of altered mechanisms.
Therefore the rationale for this study is to prospectively investigate the outcomes of patients undergoing standard dietetic interventions alongside treatment for their advanced gastrointestinal cancers, and to further characterise the relationship with body composition.
A number of patients will be enrolled in a sub-study investigating the neuronal-enteroendocrine-hypothalamic axis.
The hypothesis is that proinflammatory cytokines produced by the tumour can not only affect appetite directly through the vagal and the central melanocortin system but also indirectly though the enhanced EEC activity; either through increased number or increased function.
In this study, the investigators will explore and compare the pattern and levels (pre-prandial and post prandial) of the pro-inflammatory cytokines and gut hormones between stage-standardised anorexic and non-anorexic cancer patients and age-matched healthy controls.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
A - main study cohort
This is the main study cohort. All patients with upper gastrointestinal (gastric, oesophageal and gastro-oesophageal) cancers attending the medical oncology clinic and commencing systemic therapy will be invited to participate.
They will receive dietician support as part of their standard treatment. They will undergo assessments of body composition as part of this assessment
No interventions assigned to this group
Sub-cohort B
This sub-cohort will be invited to undergo more detailed fitness testing in the form of cardio-pulmonary exercise testing in addition to their routine care in the main cohort
No interventions assigned to this group
sub-cohort C
This sub-cohort will be invited to undergo an assessment of gut hormone and cytokine levels in addition to their routine care in the main cohort
No interventions assigned to this group
Cohort D
This is a cohort of healthy volunteers invited to act as a control to cohort C and undergo the gut hormone assessment
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Histologically proven adenocarcinoma, squamous cell carcinoma or poorly differentiated carcinoma
3. Patients should be chemotherapy or immune therapy naïve (for their current diagnosis).
4. Patient must be 18 years of age or above.
5. Patient must be able to understand the study information given to them and be willing to give consent for trial participation.
6. Patients should be commencing a course of palliative chemotherapy treatment with the upper GI team at the Christie Hospital
In addition the above patients enrolled in cohort B must meet the following criteria
1\. Be physically able to perform moderate exercise (to their own tolerance) on a stationary bicycle or treadmill
In addition to the above patients in cohort C must meet the following criteria
1. Histologically proven adenocarcinoma or poorly differentiated carcinoma
2. Patients should be chemotherapy or immune therapy naïve.
3. Patients must be able and willing to fast for 8-10 hours. 4 5.1 Patients in the anorexic group must have completed the FAACT AC/S questionnaire and scored ≤24 in total score and ≤ 2 in the appetite specific question.
5.2 For inclusion in the non-anorexic group patients must have completed the FAACT AC/S questionnaire; the total score should be \> 37 and ≥3 for the appetite specific question.
1. Participants must be 18 years of age or above.
2. Participants must be able and willing to fast for 8-10 hours.
3. Participants must be able to understand the study information given to them and be willing to give consent for trial participation.
4. Participants must have completed the FAACT AC/S questionnaire and scored ≤24 in total score and ≤ 2 in the appetite specific question, for the anorexic group. For inclusion in the non-anorexic group the total score should be \> 37 and ≥3 for the appetite specific question.
Exclusion Criteria
1. Patients unable to give informed consent
2. Patients not undergoing systemic anti-cancer treatment at The Christie hospital, for example patients not deemed fit enough for treatment, patients having alternative treatments such as radiotherapy or surgery, or patients referred for 2nd opinions.
1. Recent myocardial infarction or stroke
2. Recent abdominal, eye or thoracic surgery
3. A recent respiratory tract infection (within 3 weeks)
4. Any chest pain on the day of the test
5. A positive COVID-19 test
1. Symptoms of dysphagia of any cause, oesophageal or gastric obstruction (assessed via medical history/O'Rourke score). Patients with O'Rourke score ≥2 will be excluded.
2. Presence of oesophageal stent or any other kind of feeding aid (nasogastric tube, nasoduodenal tube, gastrostomy, jejunostomy)
3. Presence of brain metastases or any kind of brain tumor including benign pituitary adenomas.
4. Histological diagnosis of neuroendocrine tumor, or mixed tumor.
5. Previous gastro-duodenal surgery.
6. History of Inflammatory Bowel Disease (Ulcerative colitis, Crohn's disease).
7. History of Coeliac disease.
8. History of endocrine disease (Diabetes mellitus, Thyroid disease, Cushing's)
9. Significant past or present eating disorder e.g. anorexia nervosa, bulimia nervosa.
10. Current active infection (general or intestinal).
11. Chronic use of immunomodulatory drugs (steroids, immunosuppressant drugs, recent use of corticosteroids would require a two week washout period prior to study assessments).
12. Chronic use of NSAIDS or aspirin. (Periodic use can be accepted).
13. Patients with pacemakers. (Contraindication for BIA).
14. Allergy to any of the ingredients of the meal test or unwillingness to consume the particular meal (Heinz Chicken soup or Heinz Mushroom soup).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Manchester
OTHER
Manchester Metropolitan University
OTHER
The Christie NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Was Mansoor
Role: PRINCIPAL_INVESTIGATOR
The Christie NHS Foundation Trust
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Christie NHS Foundation Trust
Manchester, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CFTSp141
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.